AssetMark Inc’s Telix Pharmaceuticals TLX Stock Holding History

AssetMark Inc’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.03K	Hold	185	–	–	﹤0.01%	3046
2026 Q2	$2.13K	Buy	185 +32	+21%	+$326	﹤0.01%	2945
2026 Q1	$1.46K	Buy	153 +108	+240%	+$823	﹤0.01%	2949
2025 Q4	$337	Buy	45 +4	+10%	+$38	﹤0.01%	3172
2025 Q3	$392	Buy	41 +23	+128%	+$282	﹤0.01%	2970
2025 Q2	$289	Buy	+18	New	+$302	﹤0.01%	2825

Other funds holding TLX

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Aspect Partners Fairfax, Virginia $264M AUM 15.76% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

AssetMark Inc's TLX Position: Q3 2026 in Review

AssetMark Inc held its Telix Pharmaceuticals (TLX) position steady in Q3 2026 at 185 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3046.

AssetMark Inc first reported a position in TLX in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.13K in Q2 2026. 10 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

AssetMark Inc held 185 shares of Telix Pharmaceuticals worth $2.03K as of Q3 2026.
AssetMark Inc left its Telix Pharmaceuticals share count unchanged in Q3 2026.
Telix Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3046 holding.
AssetMark Inc first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
AssetMark Inc's Telix Pharmaceuticals position peaked at $2.13K in Q2 2026.
10 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.